Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Gujarat Themis Biosyn has informed that the Company has completed the expansion of its Fermentation Block at its manufacturing facilities at Vapi, Gujarat. The first batch of commercial production of Rifamycin-S and Rifamycin-O has commenced today, Saturday, October 18, 2025. With this expansion, the overall fermentation capacity of the Company has increased from 450 KL to 990 KL. This will further strengthen the Company’s manufacturing capabilities to produce multiple fermentation products. With this capacity expansion, the Company is in a strong position to capitalise on the significant growth opportunities in the fermentation segment.
The above information is a part of company’s filings submitted to BSE.
